<DOC>
	<DOCNO>NCT01913158</DOCNO>
	<brief_summary>The primary objective study determine safety efficacy G &amp; W Laboratories ' Anucort HC TM ( Hydrocortisone Acetate ) 25mg Rectal Suppositories subject internal hemorrhoidal symptom .</brief_summary>
	<brief_title>Safety Efficacy Study Anucort HC TM 25mg Rectal Suppositories Treat Symptomatic Internal Hemorrhoids</brief_title>
	<detailed_description>This randomize , vehicle-controlled , multicenter , double blind study Anucort HC TM ( Hydrocortisone Acetate ) 25mg Rectal Suppositories subject symptomatic internal hemorrhoid . Subjects randomly assign 1:1 ratio Test product Vehicle , respectively . Clinical evaluation perform : Visit 1/Day -3 ( -1 day ) Day 1 Screening Visit 2/Day 1 Randomization ( Start Treatment ) Visit 3/Day 8 ( -1/+3 day ) Interim Visit 4/Day 15 ( -1/+3 day ) End Treatment / Early Termination Visit 5/ Day 28 ( -1/+3 day ) * 2 Weeks Post-Treatment/Follow-Up Phone Contact Safety assess monitor adverse event ( AEs ) clinically significant change Visit 1/Screening laboratory value . Number Sites : Approximately 31 site United States .</detailed_description>
	<mesh_term>Hemorrhoids</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects diagnosis symptomatic internal hemorrhoid select participate study . 2 . Eligible subject male nonpregnant , nonlactating , nonmenstruating female ; â‰¥ 18 year age ; diagnosis Grade I , II III internal hemorrhoidal disease . 3 . For study entry subject must anorectal bleed least 2 4 recent attempt successful bowel movement prior Screening . 4 . Subject may also one symptom : pain , itch throb . 5 . At Visit 2/Day 1 ( Randomization ) subject must record least 2 instance anorectal bleed 1 incidence anorectal bleeding attempt successful bowel movement screen period Visit 1/ Day 3 ( Screening ) prior Visit 2/Day 1 ( Randomization ) . Exclusion Criteria 1 . History permanent fullthickness rectal prolapse . 2 . Current anal fissure and/or infective anal pathology . 3 . Previous history surgery anorectal disease ( within 1 year ) anorectal procedures 4 . Subjects mentally incapacitate informed consent obtain . 5 . Clinically significant comorbid condition . 6 . Diagnosis Inflammatory Bowel Disease ( IBD ) . 7 . Evidence history fecal incontinence . 8 . Clinically significant Laboratory value hematology chemistry . 9 . Subjects oral , transdermal , injectable steroid therapy within day Visit 1/Screening . 10 . Presence fissure fistulainano , abscess , severe diverticular disease , polyps colorectal adenoma colorectal cancer , arteriovenous malformation , pathological condition anus , colon rectum symptomatic internal hemorrhoid might potential cause hematochezia . 11 . Clinically significant systemic disease . 12 . Pelvic radiation past present . 13 . Use venotropic medication within 7 day Visit 2/Day 1 . 14 . Use anticoagulant medication within 10 day Visit 2/Day 1 . 15 . Use topical/anorectal corticosteroid hemorrhoidal therapy within 7 day Visit 2/Day 1 . 16 . Use topical/anorectal medicate hemorrhoidal therapy within 24 hour Visit 2/Day 1 . 17 . Unable cease use OTC prescription medication treatment hemorrhoidal disease study period . 18 . Immunocompromised subject . 19 . Known hypersensitivity allergy Hydrocortisone Acetate component IP ( dosage form ) . 20 . Use investigational drug investigational device within 30 day prior randomization . 21 . Previous participation study . 22 . Subject consumes excessive alcohol , abuse drug , condition could compromise subject ability comply study requirement . 23 . Subjects unable spontaneous bowl movement every day prior randomization . 24 . Rectal varicies portal hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>